Drug Trial Radar · NCT04126135
Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,307
Actual
Start
Jan 27, 2022
Primary completion
Mar 4, 2024
Study completion Apr 20, 2024
Sponsor
- Lead sponsor
- Loma Linda UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer; Mongolian National University of Medical Sciences
- First posted
- Oct 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A pragmatic, single blinded, randomized, controlled non-inferiority trial of Cytisine versus Nicotine Replacement Therapy for continuous abstinence is conducted in the government run primary health hospitals in Mongolia.
Conditions
- Nicotine Addiction
Interventions
CytisineDrug
Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
Nicotine Replacement Therapy (NRT)Drug
Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Length of abstinence after 25 day course of Cytisine.Time frame: One month after quit date
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mongolian National University of Medical Sciences
Ulaanbaatar, Mongolia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.